Reykjavik and Los Angeles  (May 11, 2022) – Alvotech Holdings S.A. (“ Alvotech S.A. ”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE: OACB), a special purpose acquisition

Alvotech and Oaktree Acquisition Corp. II establish financing facilities to enhance the company’s capital position and to replace any redeemed capital as part of their proposed merger. Parties agree to reduce the minimum cash condition outlined in the merger agreement, thereby enhancing deal

Upon launch, HUKYNDRA ®  will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market. All intellectual-property disputes related to market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved. Reykjavik, Iceland & Bad Vilbel, Germany.

Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023. All ongoing U.S. disputes between AbbVie and Alvotech have been resolved, including the ITC action brought forth in December 2021. Reykjavik, Iceland (March 8, 2022)  — Alvotech

Alvotech is the only known company to have both developed a high-concentration biosimilar to Humira and conducted a switching study to support interchangeability. Reykjavik, Iceland (February 28, 2022)  — Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the

Fuji and Alvotech partnership now covers six proposed biosimilar products. Reykjavik, Iceland & TOKYO, JAPAN (February 23, 2022)  — Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients

Reykjavik, Iceland & Leiden, The NetherlandS (February 2, 2022)  — Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, has entered into an exclusive global licensing agreement with

Reykjavik  (January 18, 2022) — Alvotech Holdings S.A. (“Alvotech”), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (“Oaktree II”) (NYSE: OACB), a publicly traded special

Health Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI™ are not subject to the statutory stay, clearing the way for the launch in the Canadian market. High-concentration formulations, previously unavailable in Canada, reflect over 80% of use in the US Market.

Alvotech received approval for AVT02 (100 mg/mL), the company’s high concentration biosimilar to Humira® (adalimumab), from the European Commission (EC) on Nov. 15. The centralized marketing authorization in the European Union (EU) follows the recommendation of the Committee for Medicinal Products